tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Eliana Merle, 104 are a BUY (77.04%), 31 are a HOLD (22.96%).
Analyst Eliana Merle, currently employed at UBS, carries an average stock price target met ratio of 45.72% that have a potential upside of 45.42% achieved within 200 days.
Eliana Merle’s has documented 278 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BBIO, BridgeBio Pharma at 11-Sep-2025.
Analyst best performing recommendations are on RAPT (RAPT THERAPEUTICS).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) at 11/7/2019. The price target of $28 was fulfilled within 1 day with a profit of $8.16 (22.57%) receiving and performance score of 225.66.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell
$18
$-5.8 (-24.37%)
$32
14 days ago
(25-Sep-2025)
1/10 (10%)
$-4.37 (-19.54%)
24
Buy
$46
$22.2 (93.28%)
$41
2 months 11 days ago
(28-Jul-2025)
20/26 (76.92%)
$27.05 (142.74%)
216
Hold
$24
$0.2 (0.84%)
$23
2 months 24 days ago
(15-Jul-2025)
5/10 (50%)
$4.25 (21.52%)
29
Hold
$26
$2.2 (9.24%)
$30
3 months 8 days ago
(01-Jul-2025)
2/3 (66.67%)
$8.18 (45.90%)
23
Hold
$29
$5.2 (21.85%)
$26
4 months 8 days ago
(01-Jun-2025)
9/13 (69.23%)
$9.86 (51.52%)
110
Which stock is Eliana Merle is most bullish on?
Which stock is Eliana Merle is most reserved on?
What Year was the first public recommendation made by Eliana Merle?
